IOVA
HEALTHCAREIovance Biotherapeutics Inc
$4.09+0.11 (+2.76%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IOVA Today?
No stock-specific AI insight has been generated for IOVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.64$5.63
$4.09
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.5%
Debt / Equity—
Trading
Volume17.0M
Avg Volume (10D)—
Shares Outstanding446.5M
IOVA News
23 articles- Why Iovance Biotherapeutics (IOVA) Is Up 5.7% After AMTAGVI-Driven Q1 Revenue Jump And Share PlanYahoo Finance·May 9, 2026
- IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%Yahoo Finance·May 8, 2026
- Iovance Biotherapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·May 7, 2026
- Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate UpdatesYahoo Finance·May 7, 2026
- Alvotech (ALVO) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- A Look At Iovance Biotherapeutics (IOVA) Valuation As Short Interest Eases And Institutions Add ExposureYahoo Finance·May 6, 2026
- Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- This Beaten-Down Growth Stock Could Soar 165%, According to Wall StreetThe Motley Fool·May 2, 2026
- Pacira (PCRX) Q1 Earnings Miss EstimatesYahoo Finance·Apr 30, 2026
- Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·Apr 30, 2026
- Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth FundingYahoo Finance·Apr 29, 2026
- Regeneron (REGN) Surpasses Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 29, 2026
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026Yahoo Finance·Apr 27, 2026
- Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?Yahoo Finance·Apr 26, 2026
- Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi DrugYahoo Finance·Apr 22, 2026
- Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA)Yahoo Finance·Apr 20, 2026
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·Apr 17, 2026
- Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains?Yahoo Finance·Apr 17, 2026
- Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?The Motley Fool·Apr 10, 2026
- Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and MoreGlobeNewswire Inc.·Apr 1, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
All 23 articles loaded
Price Data
Open$3.99
Previous Close$3.98
Day High$4.15
Day Low$3.91
52 Week High$5.63
52 Week Low$1.64
52-Week Range
$1.64$5.63
$4.09
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.5%
Debt / Equity—
Trading
Volume17.0M
Avg Volume (10D)—
Shares Outstanding446.5M
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—